Hao LiangYu, Zheng Lixiang
Basic Medical Research Center, Jiangxi University of Chinese Medicine, Nanchang City, Jiangxi Province, China.
PeerJ. 2025 Jul 9;13:e19703. doi: 10.7717/peerj.19703. eCollection 2025.
The marked heterogeneity of breast cancer results in substantial variations in clinical characteristics, metastatic patterns, and prognosis across molecular subtypes. However, circulating tumor cells (CTCs) and circulating tumor cell clusters (CTC clusters), pivotal mediators of metastasis, have not been comprehensively evaluated for their biological characteristics and clinical significance across molecular subtypes. This review synthesizes recent research advancements to comprehensively examine the distribution characteristics, biological functions, and prognostic associations of CTCs and CTC clusters in luminal A, luminal B, HER2-positive breast cancer, and triple-negative breast cancer (TNBC). It was observed that HER2-positive breast cancer is associated with elevated CTC counts, whereas TNBC, despite lower CTC counts, exhibits CTCs and CTC clusters with enhanced invasiveness and metastatic potential due to Notch1 signaling pathway activation, elevated PD-L1 expression, and desialylation modifications. In luminal subtypes, the scarcity of CTC clusters is linked to a reduced metastatic risk; however, luminal B exhibits a greater propensity for CTC cluster formation than luminal A, suggesting prognostic differences. Clinical data demonstrate that CTC cluster counts are significantly inversely correlated with overall survival (OS) and disease-free survival (DFS), and that dynamic monitoring of CTC clusters enables prediction of treatment resistance and recurrence risk. Furthermore, the molecular profiles of CTCs (, HER2 status, ESR1 mutations) facilitate personalized guidance for targeted and endocrine therapies. However, current detection technologies exhibit limitations in capturing CTC clusters with high efficiency and sensitivity, necessitating further optimization through microfluidic sorting, single-cell omics, and artificial intelligence approaches. This review underscores the heterogeneity of CTCs and CTC clusters across breast cancer subtypes, alongside their potential for clinical translation, offering theoretical support for prognostic evaluation and individualized treatment strategies in precision medicine. This study may be of considerable value to researchers and clinicians in the field of cancer metastasis.
乳腺癌显著的异质性导致不同分子亚型在临床特征、转移模式和预后方面存在很大差异。然而,作为转移的关键介质,循环肿瘤细胞(CTC)和循环肿瘤细胞簇(CTC簇)在不同分子亚型中的生物学特性和临床意义尚未得到全面评估。本综述综合了近期的研究进展,全面研究了腔面A型、腔面B型、HER2阳性乳腺癌和三阴性乳腺癌(TNBC)中CTC和CTC簇的分布特征、生物学功能及预后相关性。研究发现,HER2阳性乳腺癌与CTC计数升高有关,而TNBC尽管CTC计数较低,但由于Notch1信号通路激活、PD-L1表达升高和去唾液酸化修饰,其CTC和CTC簇具有更强的侵袭性和转移潜能。在腔面亚型中,CTC簇的稀缺与转移风险降低有关;然而,腔面B型比腔面A型更倾向于形成CTC簇,提示预后存在差异。临床数据表明,CTC簇计数与总生存期(OS)和无病生存期(DFS)显著负相关,动态监测CTC簇能够预测治疗耐药性和复发风险。此外,CTC的分子特征(如HER2状态、ESR1突变)有助于为靶向治疗和内分泌治疗提供个性化指导。然而,目前的检测技术在高效、灵敏地捕获CTC簇方面存在局限性,需要通过微流控分选、单细胞组学和人工智能方法进一步优化。本综述强调了乳腺癌各亚型中CTC和CTC簇的异质性及其临床转化潜力,为精准医学中的预后评估和个体化治疗策略提供了理论支持。本研究可能对癌症转移领域的研究人员和临床医生具有重要价值。